Brought to you by 
Bard buys Edwards's LifeStent for $74mm
16 Nov 2022
Executive Summary
CR Bard (vascular, urological, cancer, and surgical devices) has purchased cardiovascular-focused Edwards Lifesciences's LifeStent product line for $74mm in cash. It may also pay $65mm upon approval for a superficial femoral artery indication ($50mm) and for the transfer of the device manufacturing ($15mm).
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bard buys Edwards's LifeStent for $74mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice